Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983795 | 0.97 | HTR7 (0.94) | HTR7HTR1ADRD3ALDH1A1LMNA | |
| SCHEMBL11829560 | 0.90 | HTR7 (0.81) | HTR7HTR1ADRD3ALDH1A1MAPT | |
| SCHEMBL20358477 | 0.89 | HTR1A (0.80) | HTR7HTR1ADRD3ALDH1A1LMNA | |
| SCHEMBL11841888 | 0.88 | HTR7 (0.79) | HTR7HTR1ADRD3ALDH1A1MAPT | |
| SCHEMBL11836473 | 0.88 | HTR7 (0.79) | HTR7HTR1ADRD3ALDH1A1MAPT | |
| SCHEMBL6974786 | 0.86 | HTR1A (0.74) | HTR7HTR1ADRD3ALDH1A1LMNA | |
| SCHEMBL7842686 | 0.86 | HTR1A (0.74) | HTR7HTR1ADRD3ALDH1A1LMNA | |
| SCHEMBL7852411 | 0.86 | HTR1A (0.74) | HTR7HTR1ADRD3ALDH1A1LMNA | |
| SCHEMBL5599556 | 0.84 | HTR7 (0.73) | HTR7HTR1ADRD3 | |
| SCHEMBL6974327 | 0.83 | HTR1A (0.70) | HTR7HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | NTSR2, HTR3B, NTSR1 | HTR7 21/4885HTR1A 28/4885DRD3 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.